TrialInternational journal of molecular sciences2023

Treatment with the Topical Antimicrobial Peptide Omiganan in Mild-to-Moderate Facial Seborrheic Dermatitis versus Ketoconazole and Placebo: Results of a Randomized Controlled Proof-of-Concept Trial.

Jannik Rousel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.